Bifogade filer
Kurs
-3,52%
Kurs
-3,52%
Open
2,27
High
2,40
Low
2,19
Close
2,19
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
4,38 MNOK
Likviditet
4,38 MNOK
Rel. mcap
0,57%
Antal aktier
1 980 100
Likviditet under dagen för detta pressmeddelande
Kalender
Est. tid* | ||
2025-08-29 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-04-25 | N/A | X-dag ordinarie utdelning TRMED 0.00 NOK |
2025-04-24 | N/A | Årsstämma |
2025-02-26 | - | Bokslutskommuniké 2024 |
2025-01-06 | - | Extra Bolagsstämma 2025 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2024-04-11 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2023-04-26 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-03-01 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | 15-10 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-04-28 | - | Årsstämma |
2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2021-03-22 | - | Extra Bolagsstämma 2021 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-10-21 | - | Extra Bolagsstämma 2020 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2020-06-10 | - | Årsstämma |
2020-05-26 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | Kvartalsrapport 2019-Q1 |
2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2019-04-25 | - | Årsstämma |
2019-02-18 | - | Extra Bolagsstämma 2019 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2018-05-30 | - | Årsstämma |
2018-05-30 | - | Kvartalsrapport 2018-Q1 |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-12-20 | - | Extra Bolagsstämma 2017 |
2017-11-22 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2017-05-24 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-23 | - | Kvartalsrapport 2016-Q3 |
2016-10-12 | - | Extra Bolagsstämma 2016 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-31 | - | Kapitalmarknadsdag 2016 |
2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2016-05-19 | - | Årsstämma |
2016-05-19 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-17 | - | Kapitalmarknadsdag 2015 |
2015-10-21 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-27 | - | Kvartalsrapport 2015-Q1 |
2015-03-09 | - | Årsstämma |
2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2025-04-04 10:52:19
4.4.2025 10:52:15 CEST | Thor Medical ASA | Mandatory notification of trade
primary insiders
Oslo, Norway, 4 April 2025: Scatec Innovation AS, a close associate of board
member of Thor Medical ASA John Andersen, has today acquired 354,453 shares in
Thor Medical ASA from its controlled subsidiary, Scatec Invest IV AS, also a
close associate of John Andersen, with a price of NOK 2.388 per share,
reflecting the last 5 days' vwap for the share. The transaction is an internal
group transaction to settle balances between the parent company and its
subsidiary.
Primary insider notifications pursuant to the market abuse regulation article 19
are attached.
This information is subject to disclosure requirements pursuant to the EU Market
Abuse Regulation article 5 and the Norwegian Securities Trading Act section
5-12.
Contacts
Gisle Bjørnstad, CFO, Scatec Innovation AS, +47 95142892,
gisle.bjornstad@scatec.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.no - http://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18484477/5914/Download%20announce
ment%20as%20PDF.pdf
20250404 - Primary insider notification - Scatec Invest IV AS and Scatec
Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18484477/5913/20250404%20-%20Prim
ary%20insider%20notification%20-%20Scatec%20Invest%20IV%20AS%20and%20Scatec%20In
novation%20AS.pdf